Event Title
Synthesis of Chromene Based Thyronamine Analogues
Presentation Type
Poster/Portfolio
Presenter Major(s)
Chemistry
Mentor Information
Matthew Hart
Department
Chemistry
Location
Henry Hall Atrium 16
Start Date
10-4-2013 2:00 PM
End Date
10-4-2013 3:00 PM
Keywords
Health, Life Science, Physical Science
Abstract
200 million people worldwide are living with a thyroid hormone imbalance, resulting in abnormal heart rates and metabolic rates. Most treatments for these conditions currently rely on regulating the thyroid hormone (TH) which can take hours or even days to take effect. However, recent discoveries have shown that these same symptoms can be regulated in only minutes by a novel TH metabolite, 3-iodothyronamine (T1AM). T1AM is a potent agonist of the Trace Amine Associated Receptor (TAAR) which is believed to mediate many of these biological effects. To date, many T1AM analogues have been described. Building on these results, we have designed a T1AM analogue with a new molecular scaffold that incorporates key structural features in a conformationally-restricted arrangement. In the laboratory, we have succeeded in synthesizing precursors to these target compounds and are currently optimizing the reactions that will convert them into promising TAAR agonists.
Synthesis of Chromene Based Thyronamine Analogues
Henry Hall Atrium 16
200 million people worldwide are living with a thyroid hormone imbalance, resulting in abnormal heart rates and metabolic rates. Most treatments for these conditions currently rely on regulating the thyroid hormone (TH) which can take hours or even days to take effect. However, recent discoveries have shown that these same symptoms can be regulated in only minutes by a novel TH metabolite, 3-iodothyronamine (T1AM). T1AM is a potent agonist of the Trace Amine Associated Receptor (TAAR) which is believed to mediate many of these biological effects. To date, many T1AM analogues have been described. Building on these results, we have designed a T1AM analogue with a new molecular scaffold that incorporates key structural features in a conformationally-restricted arrangement. In the laboratory, we have succeeded in synthesizing precursors to these target compounds and are currently optimizing the reactions that will convert them into promising TAAR agonists.